Analysis of Treatment Costs for HIV RNA Reductions and CD4 Increases for Darunavir Versus Other Antiretrovirals in Treatment-Experienced, HIV–Infected Patients

REFERENCES

• Hammer SM, Saag MS, Schechter M, et al. Treatment for adult HIV infection: 2006 recommendations of the Inter-national AIDS Society-USA panel. JAMA. 2006,296:827–843.
   PubMed Web of Science ®Google Scholar
• Bartlett J, DeMasi R, Quinn J, Moxham C, Rousseau, F. Overview of the effectiveness of triple combination ther-apy in antiretroviral-naive HIV-1 infected adults. AIDS. 2001;15(11):1369–1377.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Daruna-vir prescribing information. Available at: www.aidsinfo.nih.gov. Accessed May 2007.
   Google Scholar
• De Meyer S, Azijn H, Surleraux D, et al. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates. Antimicrob Agents Chemother 2005;49:2314–2321.
   PubMed Web of Science ®Google Scholar
• Arasteh K, Clumeck N, Pozniak A, et al. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof of principle trial. AIDS. 2005;19:943–947.
   PubMed Web of Science ®Google Scholar
• Katlama C, Berger D, Bellos N, et al. Efficacy of TMC114/r in 3-class experienced patients with limited treatment op-tions: 24-week planned interim analysis of 2 96-week mul-tinational dose-finding trials. In: Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections; February 2005; Boston, Massachusetts, USA. Abstract 164LB.
   Google Scholar
• Katlama C, Carvalho M, Cooper D, et al. POWER 1 (TMC-114-C213 Study) week 24 analysis. In: Program and ab-stracts of the Third IAS Conference on HIV Pathogenesis; July 2005; Rio de Janeiro, Brazil. Abstract We0aLB0102.
   Google Scholar
• Wilkin T, Haubrich R, Steinhart C, et al. POWER 2 (TMC114-202 study). Week 24 Efficacy analysis. In: Program and ab-stracts of ICAAC; December 2005; Washington, DC, USA. Abstract H–1094.
   Google Scholar
• Reyataz® (atazanavir sulfate). US prescribing information. Bristol Myers Squibb Company. Revised July 2004. (www.reyataz.com)
   Google Scholar
• Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in pa-tients experiencing multiple virological failures. AIDS. 2005;19:685–694.
   PubMed Web of Science ®Google Scholar
• Lexiva® (fosamprenavir calcium). US prescribing informa-tion. GlaxoSmithKilneNertex, May 2004. (www.lexiva.com)
   Google Scholar
• Best B, Haubrich R. Tipranavir: a protease inhibitor for multi-drug resistant HIV-1. Exper Opin Invest Drugs. 2006;15(1):59–70.
   PubMed Web of Science ®Google Scholar
• Aptivus® (tipranavir). Prescribing information. Boeringher-Ingleheim Pharmaceuticals, Ingelheim, Germany. Available online: www.aptivus.com. Accessed April 2006.
   Google Scholar
• Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348: 2175–2185.
   PubMed Web of Science ®Google Scholar
• Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant human immunode-ficiency virus type 1 in Europe and Australia. N Engl J Med. 2003;348:2186–2195.
   PubMed Web of Science ®Google Scholar
• Squires K, Pozniak AL, Pierone G, et al. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: a random-ized trial. Ann Intern Med. 2003;139(5 pt 1):313–320.
   PubMed Web of Science ®Google Scholar
• Katlama C, Clotet B, Plettenberg A, et al. The role of aba-cavir (ABC, 1592) in antiretroviral therapy-experienced pa-tients: results from a randomised, double-blind trial. AIDS. 2000;14:781–789.
   PubMed Web of Science ®Google Scholar
• CAESAR Coordinating Committee. Randomised trial of ad-dition of lamivudine or lamivudine plus loviride to zidovu-dine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet. 1997;349(9063):1413–1421.
   PubMed Web of Science ®Google Scholar
• Gebo K, Fleishman J, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. In: Program and abstracts of the 13th Conference on Retroviruses and Op-portunistic Infections; February 2006; Denver, Colorado, USA. Abstract 537.
   Google Scholar
• Chen R, Accortt, N, Westfall A, et al. Distribution of health-care expenditures for HIV-infected patients. Clin Infect Dis. 2006;42:1002–1010.
   Web of Science ®Google Scholar
• Ledergerber B, Lundgren J, Walker A, et al. Predictors of trend in CD4-positive T cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51–62.
   PubMed Web of Science ®Google Scholar
• Benzie A, Bansi L, Sabin C, Walsh J, Phillips A. Viral rebound in patients on HAART with viral suppression. Presented at the BHIVA Spring Conference; April 2006; Brighton, UK [abstract 09]. HIV Med. 2006;7\(suppl 1):1–9.
   Google Scholar
• DeMasi R, Thommes J, Graham N. Currently marketed nucleos(t)ides provide only marginal additional viral load (VL) suppression to regimens including enfuvirtide (ENF) and boosted Pis (Pl/r) in triple class experienced patients. In: Program and abstracts of the XVI International AIDS Conference; August 2006; Toronto, Canada. Abstract THPE0125.
   Google Scholar
• Hughes MD. Initial treatment of HIV infection: randomized trials with clinical end points are still needed. J Infect Dis. 2006;194:542–544.
   PubMed Web of Science ®Google Scholar
• Basu RP, Grimes RM, Helmy A. Cost to achieve an unde-tectable viral load using recommended antiretroviral regi-mens. HIV Clin Trials. 2006;7:309–318.
   Google Scholar